CRMD · CIK 1410098
What CorMedix Inc. told the SEC could break it.
CorMedix's disclosures describe a single-product company — its catheter-infection drug DefenCath — concentrated on both ends of its chain. Its revenue leans on a few buyers, with the top three customers at 79% of 2025 revenue (one alone 38%) and no purchase commitments, while on the supply side it owns no manufacturing and depends on a single FDA-approved contract manufacturer for each of DefenCath's two key active ingredients, taurolidine and heparin sodium. Sales also hinge on reimbursement: coverage and payment levels from Medicare, Medicaid and other payors — including the inpatient NTAP add-on, subject to periodic CMS rulemaking — directly shape demand and price.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Top three customers = 79% of total revenuehigh
CorMedix derives most revenue from a few customers: the top three accounted for 79% of 2025 revenue (one customer alone 38%, and 86% in 2024), with no purchase commitments — a heavy concentration for the DefenCath maker.
“Sales to our top three customers accounted for 79% of our total revenue for the year ended December 31, 2025, and we had three customers that accounted for 41%, 23% and 20% of our accounts receivable, respectively, for the year ended December 31, 2025.”
SEC filing →As of 2026
Sole-source dependency
- Single FDA-approved CMO per API (taurolidine, heparin sodium)high
CorMedix owns no manufacturing and relies on a single FDA-approved contract manufacturer for each of DefenCath's two key APIs — taurolidine and heparin sodium — creating single-source supply risk.
“For DefenCath, the Company currently has one FDA-approved source (contract manufacturing organization, or “CMO”) for each of its two key active pharmaceutical ingredients (“APIs”), taurolidine and heparin sodium, respectively.”
SEC filing →As of 2026
Regulatory & policy
- Third-party payor / CMS reimbursement dependence (NTAP)medium
DefenCath sales depend heavily on Medicare, Medicaid and other payor coverage and reimbursement levels (including the inpatient NTAP), which are subject to periodic CMS rulemaking and could reduce demand or price.
“Sales of DefenCath depend, in large part, on the extent to which it will be covered by third-party payors, such as Medicare, Medicaid, and other federal and state government programs, managed care entities, commercial insurers, and other organizations, as well as the level of reimburse”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch